Skip to Content
Søg Menu
Vi dækker

ESMO I European Society for Medical Oncology

ESMO 2025

ESMO_kongresside

  • / marie

Artikler fra ESMO 2025

MEDtalks fra ESMO 2025

ESMO 2024

ESMO_kongresside

  • / marie

ESMO_kongresside

/ marie

Highlights fra ESMO 2024

Louise Wichmann Matthiessen

Highlights: Det kliniske landskab for brystkræft efter ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video
Dag Rune Stormoen

Highlights fra ESMO 2024: Non-muskelinvasiv, muskelinvasiv og metastatisk / lokal-avanceret blærecancer

/ Dag Rune Stormoen
ESMO24Blærecancer Play the Video
Morten Mau-sørensen

Highlights fra ESMO 2024 for øvre gastrointestinal cancer

/ Morten Mau-Sørensen
ESMO24Gastrointestinal cancer Play the Video
Jens Benn Sørensen

Highlights fra ESMO 2024 om lungecancer

/ Jens Benn Sørensen
ESMO24Lungecancer Play the Video
Charlotte Aa. Hasund

ESMO 2024: Highlights for ovariecancer og endometricancer

/ Charlotte Haslund
ESMO24Gynækologisk cancer Play the Video
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video

Top 4 mest sete MEDtalks fra ESMO 2024

Abstracts fra ESMO 2024

ESMO_kongresside

  • / marie

ESMO 2023 • Meet the experts

Get access

ESMO 2022

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Onkologi / Eric Pujade-Lauraine

Global consensus: Management of epithelioid hemangioendothelioma

/ Onkologi / Silvia Stacchiotti

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Onkologi / Eric Pujade-Lauraine

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Onkologi / Alan Celik

Opdatering på CheckMate 649-studiet

/ Onkologi / Lene Bæksgaard
Se oversigt

ESMO 2021

High-risk factors in patients with advanced ovarian cancer impact survival

/ Onkologi / Dana Chase

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Onkologi / Ma Pilar Barretina-Ginesta

Klinisk perspektivering af COAST-studiet for patienter med metastatisk ikke-operable stadie III ikke-småcellet lungecancer

/ Onkologi / Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Onkologi / Roy S. Herbst

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Onkologi / Camillo Porta
Se oversigt

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Onkologi / Jared Weiss

Perspective of first line immune therapy of non-small-cell lung cancer

/ Onkologi / Ahmet Sezer

Dansk real-life studie viser, at prognosen for malignt melanom med hjernemetastaser er forbedret siden 2015

/ Onkologi / Sidsel Pedersen

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Onkologi / Nir Peled

Immunterapi har positiv effekt på ubehandlede hjernemetastaser ved ikke-småcellet lungecancer

/ Onkologi / Birgitte Bjørnhart
Se oversigt

Dobbelt immunterapi giver fortsat bedre overlevelse ved malignt pleural mesotheliom

/ Onkologi / Jens Benn Sørensen

Potential as new standard treatment of HER2+ metastatic breast cancer

/ Onkologi / Javier Cortés

IL-6 receptor hæmmer dæmper bivirkninger ved immun checkpoint hæmmer behandling

/ Onkologi / Rikke Bødker Holmstrøm

Nivolumab + chemo – a candidate for a new standard 1L treatment of advanced gastric/esophageal adenocarcinoma

/ Onkologi / Yelena Janjigian

Real-world data on effectiveness of durvalumab after chemoradiotherapy

/ Onkologi / Nicolas Girard
Se oversigt

Back to top